GlaxoSmithKline, the UK’s biggest pharmaceutical company, has been ordered to review its global manufacturing operations after it was discovered a Canadian subsidiary failed to meet quality requirements during production of a flu vaccine.
The production of FluLaval by Quebec-based ID Biomedical, which helped make £150m for GSK last year after 26m global sales, is under review from America’s Food and Drug Administration. Citing “deviations from current good manufacturing practice, the news is a further blow to the company following a string of incidents which have included corruption allegations…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
